Endece
Private Company
Funding information not available
Overview
Endece is a neuroscience-focused biotech developing NDC-1308, a novel small molecule with a dual mechanism of action targeting remyelination and demyelination for neurodegenerative diseases like multiple sclerosis (MS). The company possesses a proprietary compound library with over 100 issued patents and is led by its founder, Dr. James Yarger, an experienced scientist and executive. Currently in the preclinical stage, Endece's strategy hinges on advancing NDC-1308 into clinical trials to address a significant unmet need in neurodegenerative diseases where current therapies primarily manage symptoms rather than repair damage.
Technology Platform
Proprietary library of small molecules designed to modify specific gene expression to restore biological function, with a lead mechanism targeting remyelination and macrophage polarization via lipoprotein lipase (LPL) upregulation.
Opportunities
Risk Factors
Competitive Landscape
Endece competes in the crowded MS market, but its dual mechanism (remyelination + demyelination inhibition) differentiates it from current immunomodulatory drugs. However, it faces direct competition from other companies (e.g., Biogen, Sanofi, smaller biotechs) also developing remyelination therapies, creating a race to demonstrate clinical proof-of-concept.